| 1.68 -0.04 (-2.33%) | 11-05 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.1 | 1-year : | 2.35 |
| Resists | First : | 1.8 | Second : | 2.01 |
| Pivot price | 1.59  |
|||
| Supports | First : | 1.45 | Second : | 1.2 |
| MAs | MA(5) : | 1.6 |
MA(20) : | 1.61 |
| MA(100) : | 1.79 |
MA(250) : | 5.03 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 50.2 |
| RSI | RSI(14): 50.7 |
|||
| 52-week | High : | 12.25 | Low : | 1.39 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ENGN ] has closed below upper band by 18.9%. Bollinger Bands are 3.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.71 - 1.72 | 1.72 - 1.73 |
| Low: | 1.63 - 1.64 | 1.64 - 1.65 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
Wed, 07 Oct 2026
enGene Holdings (ENGN) Slides 3.74% to $1.80 as Shares Drift Toward $1.71 Support - Pullback Trade - siam.in
Thu, 10 Sep 2026
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The Market - Seeking Alpha
Sat, 18 Jul 2026
enGene Holdings appoints new chairman to guide growth - The Globe and Mail
Wed, 08 Apr 2026
enGene Therapeutics (Nasdaq:ENGN) - Stock Analysis - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 67 (M) |
| Shares Float | 33 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 83.6 (%) |
| Shares Short | 1,390 (K) |
| Shares Short P.Month | 1,230 (K) |
| EPS | -2.07 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.44 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32 % |
| Return on Equity (ttm) | -60.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.03 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -103 (M) |
| Levered Free Cash Flow | -61 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.48 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.09 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|